Supplemental Filings: CBER/CDER Real-Time Comms, DCT Fall Off, Mifepristone REMS

US CBER director Peter Marks suggests CDER could join its real-time communications pilot program, CDER's Jacqueline Corrigan-Curay says the use of decentralized trials has declined since the pandemic eased, and the GAO concludes that revisions to the mifepristone REMS do not require congressional review.